Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1561 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Andrea Francesco Daniele Di Stefano und 8 weiteren Autor:innen. Beteiligte Einrichtung: CROSS Research S.A., CH-6864 Arzo, Switzerland. Hauptthemen laut MEDLINE: Cortodoxone, Acne Vulgaris, Androgen Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne. Studies CB‐03‐01/02 (EudraCT: 2007‐005064‐28) and CB‐03‐01/04 (n = 24 each) assessed PK in healthy participants. Study 171‐7151‐203 (n = 8) assessed steady‐state PK in patients with acne. Studies CB‐03‐01/05 (n = 36) and CB‐03‐01/32 (n = 250) assessed skin irritation and sensitization potential, respectively, in healthy participants. Systemic exposure to clascoterone was low after repeated daily application for up to 42 days of treatment. Clascoterone was excreted in urine as conjugated esters at a ≤1% fraction of the administered dose. Adverse events and local skin reactions were generally mild/moderate and reversible. No clinically relevant changes were observed in laboratory tests and vital signs. Skin irritation and sensitization with clascoterone treatment were minimal. Phase 1 study findings supported low systemic absorption of clascoterone and a favorable safety profile after topical application of clascoterone cream 1%, with no evidence of irritation or sensitization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CROSS Research S.A., CH-6864 Arzo, Switzerland.
- Medical University of Vienna, Vienna, Austria.
- Cassiopea, Inc., San Diego, CA, USA.
- Novan, Inc., Durham, NC, USA.
- Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
- Cassiopea S.p.A., Lainate, Italy.
Zitieren
APA
Di Stefano, A. F. D., Radicioni, M. M., Garhöfer, G., Cartwright, M., Müller, M., Kopeloff, I., Moro, L., Squittieri, N., & Mazzetti, A. (2025). Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1561
Vancouver
Di Stefano AFD, Radicioni MM, Garhöfer G, Cartwright M, Müller M, Kopeloff I, et al. Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1561
BibTeX
@article{DiStefano2025,
author = {Di Stefano, Andrea Francesco Daniele and Radicioni, Milko Massimiliano and Garhöfer, Gerhard and Cartwright, Martina and Müller, Markus and Kopeloff, Iris and Moro, Luigi and Squittieri, Nicholas and Mazzetti, Alessandro},
title = {Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1561}
}
EUVIMED